James Feldman, MD
Cardiovascular Disease · Houston, TXNPI 1306860457
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by GE HealthCare at 47.8% of the total. Reporting peaked in 2022 at $11,921 and has fallen 93.0% since, to $840 in 2025.
Across 302 payments — averaging $70.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$10K
- Abbott$3K
- Boston Scientific$2K
- Johnson & Johnson$1K
- Novartis$639
- Medtronic$479
- plus $3K from 30 others
Across 496 payments — averaging $6146.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GE HealthCare$1M
- Janssen Research & Development, LLC$984K
- Merck$379K
- Boehringer Ingelheim International GmbH$237K
- Boehringer Ingelheim Pharma GmbH & Co.kg$234K
- Novartis$185K
- plus $22K from 4 others
What the payments were for
- Consulting fees$10,20048%
- Travel & lodging$9955%
- Food & beverage$10,09947%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 1 | $10,200 |
| Abbott | 42 | $3,020 |
| Boston Scientific | 32 | $2,325 |
| Johnson & Johnson | 56 | $1,204 |
| Novartis | 38 | $639 |
| Medtronic(2 entities) | 10 | $479 |
| Amgen | 26 | $457 |
| Edwards Lifesciences | 3 | $400 |
| Abiomed | 3 | $358 |
| E.r. Squibb & Sons, L.L.C. | 18 | $268 |
| Biotronik Inc. | 2 | $198 |
| Impulse Dynamics (USA) Inc. | 3 | $196 |
| Merck | 11 | $190 |
| Amarin Pharma, Inc. | 3 | $148 |
| Melinta Therapeutics, LLC | 1 | $122 |
| Pfizer | 6 | $121 |
| Philips North America LLC | 1 | $112 |
| AbbVie | 1 | $104 |
| Esperion Therapeutics, Inc. | 6 | $92 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| AstraZeneca | 5 | $70 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $60 |
| Novo Nordisk | 3 | $55 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Bard Peripheral Vascular, Inc. | 1 | $45 |
| Cardiva Medical, Inc. | 2 | $42 |
| Stryker | 1 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| Tactile Systems Technology Inc | 2 | $40 |
| Boehringer Ingelheim | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Cvrx, Inc. | 1 | $14 |
| Preventice Services, LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM$1,210
- JOT DX$807
- Confirm Rx$571
- Impella$358
- XARELTO$348
- Micra$304
- AVEIR$250
- OPTIMIZER$163
- Orsiro Mission$160
- COMET$137
- GENERAL BRADY$125
- Baxdela$122
- Vascepa$120
- MitraClip$115
- (9520) IGT Devices Undivided$112
- AVYCAZ$104
- Watchman$103
- GENERAL TACHY$102
How this compares
$21,322 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 455 | $525,317 |
| XareltoRivaroxaban | 352 | $404,375 |
| EntrestoSacubitril/Valsartan | 101 | $157,129 |
| Repatha SureclickEvolocumab | 67 | $73,346 |
| BrilintaTicagrelor | 51 | $48,834 |
| MultaqDronedarone Hcl | 31 | $40,563 |
| JardianceEmpagliflozin | 34 | $27,358 |
| FarxigaDapagliflozin Propanediol | 22 | $24,980 |
| OzempicSemaglutide | 12 | $13,098 |
| Atorvastatin Calcium | 1,318 | $13,095 |
| Metoprolol Succinate | 908 | $12,752 |
| Losartan Potassium | 757 | $8,372 |
| Valsartan | 283 | $8,177 |
| Rosuvastatin Calcium | 478 | $7,642 |
| Clonidine | 28 | $5,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $121 | $525,317455 claims |
| Johnson & JohnsonXarelto | $1,204 | $404,375352 claims |
| NovartisEntresto | $639 | $157,129101 claims |
| AstraZenecaBrilinta, Farxiga | $70 | $73,81373 claims |
| Sanofi-aventis U.S. LLCMultaq | $75 | $40,56331 claims |
| Boehringer IngelheimJardiance | $33 | $27,35834 claims |
| Novo NordiskOzempic | $55 | $13,09812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.